Carrero J J, Qureshi A R, Axelsson J, Yilmaz M I, Rehnmark S, Witt M R, Bárány P, Heimbürger O, Suliman M E, Alvestrand A, Lindholm B, Stenvinkel P
Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
J Intern Med. 2007 Dec;262(6):690-701. doi: 10.1111/j.1365-2796.2007.01865.x. Epub 2007 Oct 1.
In this study, we explore the associations of decreased thyroid hormone levels with inflammation, wasting and survival in biochemically euthyroid patients with end-stage renal disease (ESRD).
After exclusion of 23 patients with thyroid-stimulating hormone (TSH) values outside the normal range (0.1-4.5 mIU L(-1)), 187 clinically and biochemically euthyroid incident ESRD stage 5 patients starting dialysis were followed for a median of 20 (range 1-60) months. Measurements of total and free forms of thyroid hormones, s-albumin, hs-CRP, interleukin (IL)-6, vascular adhesion molecule (VCAM)-1 and insulin-like growth factor 1 (IGF-1) were performed at baseline.
In this population, 17 out of 210 patients (8%) were defined as subclinically hypothyroid. Multivariate analysis, according to receiver operating characteristic (ROC) curves, showed that mortality was best predicted by total triiodothyronine (T3). When using the cut-off levels derived from ROC, low T3 levels were associated with increased inflammation (higher hs-CRP, IL-6 and VCAM-1) and lower concentration of both s-albumin and IGF-1. Finally, low T3 but not low free triiodothyronine was associated with worse all-cause (Likelihood ratio = 45.4; P < 0.0001) and cardiovascular mortality (Likelihood ratio = 47.8; P < 0.0001) after adjustment for confounding factors.
This study showed that low T3 levels are independent predictors of all-cause and also cardiovascular disease mortality in biochemically euthyroid patients, perhaps due to an intimate association with inflammation. Based on these results, the use of T3 levels in studies assessing the relationship between thyroid dysfunction and mortality risk is recommended.
在本研究中,我们探讨甲状腺激素水平降低与终末期肾病(ESRD)生化甲状腺功能正常患者的炎症、消瘦和生存之间的关联。
排除23例促甲状腺激素(TSH)值超出正常范围(0.1 - 4.5 mIU/L)的患者后,对187例开始透析的临床和生化甲状腺功能正常的初发ESRD 5期患者进行了中位时间为20(范围1 - 60)个月的随访。在基线时测量了甲状腺激素的总形式和游离形式、血清白蛋白、高敏C反应蛋白(hs-CRP)、白细胞介素(IL)-6、血管细胞黏附分子(VCAM)-1和胰岛素样生长因子1(IGF-1)。
在该人群中,210例患者中有17例(8%)被定义为亚临床甲状腺功能减退。根据受试者工作特征(ROC)曲线进行的多因素分析表明,总三碘甲状腺原氨酸(T3)对死亡率的预测效果最佳。当使用从ROC得出的临界值时,低T3水平与炎症增加(更高的hs-CRP、IL-6和VCAM-1)以及血清白蛋白和IGF-1浓度降低相关。最后,在调整混杂因素后,低T3而非低游离三碘甲状腺原氨酸与全因死亡率(似然比 = 45.4;P < 0.0001)和心血管死亡率(似然比 = 47.8;P < 0.0001)升高相关。
本研究表明,低T3水平是生化甲状腺功能正常患者全因死亡率以及心血管疾病死亡率的独立预测因素,这可能是由于其与炎症密切相关。基于这些结果,建议在评估甲状腺功能障碍与死亡风险之间关系的研究中使用T3水平。